| 英文别名 |
Orelabrutinib;6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide;WJA5UO9E10;orelabrutinib (proposed INN);ICP022;US9951056, Example 3;GTPL10629;MZPVEMOYADUARK-UHFFFAOYSA-N;BDBM389631;example 3 [WO2015048662A2];ICP-022;6-[1-(1-Oxo-2-propen-1-yl)-4-piperidinyl]-2-(4-phenoxyphenyl)-3-pyridinecarboxamide;AC-36680;HY-129390;CHEMBL4650321;BTK Inhibitor ICP-022;AKOS040733921;6-(1-(1-Oxo-2-propen-1-yl)-4-piperidinyl)-2-(4-phenoxyphenyl)-3-pyridinecarboxamide;EX-A3442;ORELABRUTINIB [WHO-DD];1655504-04-3;3-Pyridinecarboxamide, 6-(1-(1-oxo-2-propen-1-yl)-4-piperidinyl)-2-(4-phenoxyphenyl)-;DB-091042;CS-0105163;Orelabrutinib (USAN/INN);UNII-WJA5UO9E10;s9600;WHO 11190;2-(4-phenoxyphenyl)-6-(1-prop-2-enoylpiperidin-4-yl)pyridine-3-carboxamide;NSC826039;INNOBRUKA;NSC-826039;D12160;2-(4-phenoxyphenyl)-6-[1-(prop-2-enoyl)piperidin-4-yl]pyridine-3-carboxamide;MS-27554;SCHEMBL16597834;Orelabrutinib [USAN:INN];Orelabrutinib [INN];Orelabrutinib [USAN];ICP 022;F88710 |
关注我们
热线：
15806766175
COA质检证书
